Nova’s (NASDAQ:NVMI) Q2 Sales Top Estimates, Inventory Levels Improve

Nova (NASDAQ:NVMI) reported Q2 CY2026 revenue of $255 million, up 15.9% year on year and 1.6% above estimates. Q3 guidance revenue was $282 million at the midpoint, 1.8% above consensus. Non-GAAP EPS was $2.51, 4.1% above estimates. Days inventory outstanding fell to 152, 30 days below its 5-year average.

Original reporting
Published Aug 6, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nova’s (NASDAQ:NVMI) Q2 Sales Top Estimates, Inventory Levels Improve — source image
Decision brief

The 30-second read

$NVMIBullishMed
01

Why it matters

Q2 revenue beat and next-quarter guidance above consensus midpoint, combined with lower-than-average DIO, point to healthier demand and reduced inventory buildup risk.

02

Market read

This is a company-specific earnings and guidance update with explicit revenue, EPS, and inventory (DIO) metrics that can drive near-term positioning.

03

What to watch

The article omits margins, backlog, customer concentration, and cash flow details; traders may need those to judge whether the guidance implies durable demand or temporary strength.

Relevance 8/10Novelty 8/10Timing: post-Q2 earnings release, shares down 1.3% immediately after reporting

Background

Nova provides semiconductor manufacturing quality control systems; the article frames results around revenue growth, guidance, and inventory risk via DIO.

Company-level read

Ticker impact

$NVMIBullishMedium confidence
Context

Nova reported Q2 CY2026 revenue of $255M, up 15.9% YoY, and guided next-quarter revenue to $282M midpoint.

Expected impact

Likely near-term upside bias versus pre-report expectations, with follow-through dependent on whether the guidance is sustained.

Evidence & confidence

The article provides concrete Q2 results, next-quarter midpoint guidance, and DIO improvement (152, 30 days below 5-year average), which collectively reduce demand-inventory risk and support the upcycle narrative.

Market effects

Improving inventory/demand signals in semiconductor quality control can be read-across to equipment and process-control spending strength during the upcycle.

Limited direct regional impact; Nova is Israel-headquartered but the catalyst is company-specific results.

Supports the broader semiconductor capex and process-control demand narrative, though impact is incremental versus major foundry/equipment prints.

Counterpoint

The stock fell 1.3% right after the report, suggesting the market may have priced in the beat and focused on valuation or higher expectations not captured here.

Key entities

  • Nova

    NASDAQ-listed semiconductor quality control systems provider reporting Q2 results and next-quarter revenue guidance.

  • Wall Street estimates

    Analysts’ consensus used as the comparison for the revenue beat and guidance midpoint.

Related articles

$NVMIMedAI 8/10

Nova (NVMI) Just Blew Past $250M In Quarterly Sales

Nova (NVMI) reported Q2 2026 revenue of $255M, up 8% QoQ and 16% YoY, with GAAP net income of $75M and non-GAAP net income of $86.5M. GAAP EPS was $2.20, up from $2.04 QoQ and $2.14 YoY. Non-GAAP EPS was $2.51, up from $2.33 QoQ and $2.20 YoY. The company guided Q3 2026 revenue to $277M-$287M, GAAP EPS to $2.46-$2.61, and non-GAAP EPS to $2.70-$2.85. Gross margin declined to 56.5% from 57.7% QoQ and 57.8% YoY.

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$NVMIHigh

NOVA LTD. (NVMI): Financial results for Q2 2026

NOVA LTD. (NVMI) furnished an SEC Form 6-K — earnings release. Attached hereto and incorporated by way of reference herein is a press release issued by the Registrant and entitled: “Nova Reports Record Second Quarter 2026 Financial Results”. The GAAP financial statements tables included in the press release attached hereto are hereby incorpo

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.